NCT00110890 - A Research Study for Patients With End-Stage Renal Disease (ESRD) | Biotech Hunter

Enrollment

552

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

April 30, 2005

Study Completion Date

September 30, 2007

Conditions

End Stage Renal Disease

Interventions

DRUG

cinacalcet

Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg.

OTHER

Standard of care

Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.